CytoSorbents Corporation (CTSO)

[biomed64]

Nice PR. The question is, how is this positioned relative to the PhaseBio news about their REVERSE-IT Phase 3 Clinical Trial going on already.
In that trial,
"Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta® (ticagrelor)."
Perhaps one of the knowledgeable members here could shed some light into the pros and cons of each.
PhaseBio popped 16% today.